SOURCE-LINKED STUDY SUMMARY
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.
Abstract summarizedQuality not appraised
- What was studied
- A double-blind phase 3 trial tested the GLP-1/glucagon dual agonist mazdutide for weight reduction.
- Who / model studied
- 610 Chinese adults with obesity or overweight plus a weight-related condition.
- Studied dose & schedule
- Mazdutide 4 mg or 6 mg once weekly versus placebo for 48 weeks.
- What the study found
- At week 48, mean weight changes were −11.00% with 4 mg, −14.01% with 6 mg and +0.30% with placebo. At least 15% weight loss occurred in 35.7%, 49.5% and 2.0%, respectively. Gastrointestinal events were most common, mostly mild or moderate.
- Limitations & context
- Chinese study population; weight change does not distinguish fat from lean tissue. There was no active-drug comparator. The primary endpoints were assessed at week 32; these figures describe week 48.
Read summary source ↗ · Prepared 9/29/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1056/nejmoa2411528